ArticleScientific reports2026
Melatonin-treated bone marrow mesenchymal stem cell-derived exosomes reverse liver fibrosis induced by CCl4 in male wistar albino rats.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver fibrosis is defined as the substitution of hepatocytes with extracellular matrix (ECM) proteins, accompanied by abnormalities in matrix remodelling. We aimed to assess the efficacy of melatonin-pretreated bone marrow mesenchymal stem cell-derived exosomes (MT/Exos) in mitigating liver fibrosis. MT/Exos were isolated from their parent cells and characterised by measuring protein content, particle size, and cluster of differentiation (CD) markers. In vivo studies (MT/Exos (100 µg/rat) via the caudal vein twice weekly for 4 weeks) include assessment of liver biomarkers, oxidative stress markers, inflammatory cytokines, apoptotic markers, fibrotic cytokines, and histopathological changes. MT/Exos with 1 mg/ml protein showed double-membrane vesicles sized 50-100 nm, and expressed CD63 and CD81 markers. Treated rats showed restoration of albumin levels, significant improvements in liver enzymes, notable elevations in SOD activity and Nrf2 levels, and a marked reduction in MDA levels. TNF-α, IL-17, NF-κB-p50, and p65 levels were attenuated, and IL-10 levels increased significantly. p53, Bax, caspase-3, TGF-β, SMAD3, collagen I, and miRNA 196 also showed a substantial decrease in treated rats (P < 0.05). Histopathological examination confirmed a marked reduction of collagen deposition and inflammatory infiltration. MT/Exos were successfully isolated and characterized. The MT/Exos-treated group showed improvements in all liver function parameters, with increased levels of antioxidant and anti-inflammatory markers. MT/Exos reduced apoptotic and fibrotic modulators and improved histopathological features. These findings confirm the synergistic effect of melatonin preconditioning in improving the therapeutic potential of MSC-derived exosomes as a novel anti-fibrotic agent. Overall, MT/Exos may offer a promising therapeutic approach for liver fibrosis with potential clinical relevance pending further studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.